On April 25, 2017, Branden Partners, L.P., doing business as Pacific Pulmonary Services, agreed to pay $11.4 million to resolve allegations that it and its general partner, Teijin Pharma USA LLC, violated the False Claims Act.  Pacific Pulmonary Services provides oxygen tanks and related supplies, and sleep therapy equipment, to patients’ homes.  The allegations were that, starting in 2004, Pacific Pulmonary Services began submitting claims for reimbursement to Medicare and other federal healthcare programs for home oxygen and oxygen equipment without obtaining a physician authorization, which is required by program rules.  In addition, the government also alleges that, starting in 2006, some of Pacific Pulmonary Services’ patient care coordinators participated in a cross-referral kickback scheme with sleep clinics, in which they agreed to make patient referrals to sleep testing clinics in exchange for the clinics’ agreement to refer patients to Pacific Pulmonary Services for sleep therapy equipment.  The settlement originated out of a qui tam lawsuit brought by a former sales representative of Pacific Pulmonary Services pursuant to the whistleblower provisions of the False Claims Act. DOJ Press Release